A double-blind, randomized, placebo and positive-controlled study in healthy volunteers to evaluate pharmacokinetic and pharmacodynamic properties of multiple oral doses of cetagliptin.
Jinmiao LuLu WangSufeng ZhouChen ZhouLijun XieJuan ChenDong TangXusheng TianDaosheng XieJuping DingTong WangQiang YuJinsong DingFeng ShaoPublished in: British journal of clinical pharmacology (2022)
Cetagliptin demonstrates the great potential for treatment with type 2 diabetes patients based on the inhibition of DPP-4, the increase in GLP-1 and insulin, the decrease in glucose, and might be more effective in DPP-4 inhibition than sitagliptin.
Keyphrases
- end stage renal disease
- double blind
- type diabetes
- ejection fraction
- chronic kidney disease
- newly diagnosed
- phase iii
- placebo controlled
- open label
- clinical trial
- prognostic factors
- randomized controlled trial
- patient reported outcomes
- adipose tissue
- glycemic control
- combination therapy
- climate change
- skeletal muscle
- insulin resistance